ARTICLE | Company News
Amylin files Symlin MAA
May 31, 2001 7:00 AM UTC
AMLN submitted an MAA for its Symlin pramlintide synthetic analog of amylin hormone to treat patients with Type I or Type II diabetes. In January, the FDA accepted for filing AMLN's NDA for Symlin. ...